Overview

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease

Status:
Suspended
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Leber's Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Retinagenix Therapeutics